Sort 2 diabetes drug reveals promise towards weight problems, examine suggests. However it’s costly


Photo credit: CC0 Public Domain

According to a study published last week in the New England Journal of Medicine, a new drug was found to be so effective against obesity that it could help patients avoid complications such as diabetes and high blood pressure.

Semaglutide is currently marketed by its maker Novo Nordisk for the treatment of type 2 diabetes. After manufacturers found that patients taking the drug lost weight over the course of treatment, Northwestern University researchers decided to test its effectiveness at a much higher dose against obesity.

The study, which was conducted at 129 centers in 16 countries, enrolled nearly 2,000 obese people who were injected with either semaglutide or a placebo weekly for 68 weeks. Both groups also received diet and exercise advice during the study. The researchers found that people who received doses of semaglutide lost, on average, nearly 15% of their body weight, while those who received the placebo lost 2.4% of their body weight. More than a third of the participants who received semaglutide lost more than 20% of their body weight.

“This is the weight management breakthrough obesity patients have been waiting for,” said Thomas Wadden, professor of psychology at the University of Pennsylvania and co-author of the paper. “I’ve been with Penn in the weight management business for 40 years and this is one of the most exciting developments I’ve seen in my career.”

The results are especially intriguing now, as obesity is viewed as a major risk factor for COVID-19 complications.

Most obesity drugs currently approved by the Food and Drug Administration (FDA) result in about a 7% reduction in body weight. With that amount of weight loss, “many people still feel overweight even after their health has improved,” he said.

Patients who took semaglutide in the study had only mild gastrointestinal symptoms such as nausea and diarrhea in the past when compared to anti-obesity drugs. Wadden also pointed out that drugs for the treatment of obesity that are currently approved for use can only be taken for a short period of time, while researchers visualize the prescription of semaglutide as a drug for a chronic condition. Additional studies will be conducted to determine the effectiveness of an increased dose of the drug in patients with type 2 diabetes who were not included in this study, as well as the maintenance of weight loss in patients.

“Patients are expected to be able to take these drugs over the long term as well as drugs for cholesterol and diabetes,” said Wadden. “This is not something that you take and stop for four months. Health care providers need to recognize that this is a chronic treatment for a chronic health problem.”

However, it’s important not to overlook the lack of research on the long-term effects of semaglutide, said Farzaneh Daghigh, a professor of biochemistry at the Philadelphia College of Osteopathic Medicine who was not involved in the study. The drug is a synthetic version of a hormone that causes feelings of fullness in the brain and intestines.

Daghigh said the drug is likely to be expensive, pointing out that the lower dose of semaglutide currently prescribed for patients with type 2 diabetes costs $ 1,000 per month.

She also warned that the study was funded by drug maker Novo Nordisk.

“When these types of pharmaceutical therapies come out, we scientists want independent groups to do this study,” she said.

Daghigh stressed that it is also important to teach people how to eat healthier foods and plant-based diets, rather than relying on drug therapies to fight obesity.

“I can see the benefit of using it in certain patients, but you can’t inject the drug forever,” she said. “If patients don’t know how to act afterward, that’s a problem. All of this makes me very reluctant to cheer.”

However, Wadden hopes the study’s results will accelerate research into anti-obesity drugs.

“The average patient in this study lost 30 pounds,” he said. “This is a significant milestone as a person can gain better control over obesity-related health complications such as high blood pressure, blood sugar, and sleep apnea. People feel different, feel different, exercise more comfortable, and buy clothes that make them feel more comfortable find attractive and play with their children and grandchildren. ”

The drug ‘Gamechanger’ used to treat obesity reduces body weight by 20%

2021 The Philadelphia Inquirer, LLC.
Distributed by Tribune Content Agency, LLC.

Quote: Type 2 diabetes drug shows promise for obesity, the study said. But it’s expensive (2021, February 16), accessed February 17, 2021 from

This document is subject to copyright. Except for fair trade for the purpose of private study or research, no part may be reproduced without written permission. The content is provided for informational purposes only.